travoprost 0.04 MG/ML Ophthalmic Solution [Travatan]
travoprost
RxCUI: 285032
What the CMS Formulary Data Shows for travoprost 0.04 MG/ML Ophthalmic Solution [Travatan]
Per the CMS 2026 Part D formulary file, travoprost 0.04 MG/ML Ophthalmic Solution [Travatan] (RxNorm concept RXCUI 285032, generic name travoprost) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.
Real-world access to travoprost 0.04 MG/ML Ophthalmic Solution [Travatan] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 123,672 Part D beneficiaries filled travoprost 0.04 MG/ML Ophthalmic Solution [Travatan] in 2023, with total plan-and-beneficiary spending of $114,118,828 and an average per-beneficiary annual cost of $922.75. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry travoprost 0.04 MG/ML Ophthalmic Solution [Travatan] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 2
- Coverage rate
- 0%
- Tier range
- Tier 1, Preferred Generic
- Average tier
- Tier 1, Preferred Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 123,672
- Total spending
- $114,118,828
- Avg per beneficiary
- $922.75
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering travoprost 0.04 MG/ML Ophthalmic Solution [Travatan]
2 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $34.50 | NY |
Frequently Asked Questions
Is travoprost 0.04 MG/ML Ophthalmic Solution [Travatan] covered by Medicare Part D?
Yes, travoprost 0.04 MG/ML Ophthalmic Solution [Travatan] is covered by 2 Medicare Part D plans (0% of all Part D formularies).
What tier is travoprost 0.04 MG/ML Ophthalmic Solution [Travatan] on Medicare Part D plans?
travoprost 0.04 MG/ML Ophthalmic Solution [Travatan] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.
Does travoprost 0.04 MG/ML Ophthalmic Solution [Travatan] require prior authorization?
0% of Part D formularies require prior authorization for travoprost 0.04 MG/ML Ophthalmic Solution [Travatan]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on travoprost 0.04 MG/ML Ophthalmic Solution [Travatan]?
In 2023, total Medicare Part D spending on travoprost 0.04 MG/ML Ophthalmic Solution [Travatan] was $114,118,828, covering 123,672 beneficiaries. The average spend per beneficiary was $922.75.
Read our methodology - how this data is sourced, computed, and verified.